ID

38504

Description

TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01282151

Link

https://clinicaltrials.gov/show/NCT01282151

Keywords

Versions (1)
  1. 10/22/19 10/22/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

October 22, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Carcinoma, Non Small Cell Lung NCT01282151

English

Eligibility Carcinoma, Non Small Cell Lung NCT01282151

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
age >= 18 years old
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
ecog performance status 0-2
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
non-squamous cell type non-small cell lung cancer (nsclc)
Description

Non-squamous non-small cell lung cancer

Data type

boolean

Alias
UMLS CUI [1]
C4324656
stage iv, stage iiib cannot be treated with curative intent or relapsed after surgery or radiation therapy
Description

TNM clinical staging | Curative treatment Unsuccessful | Recurrent disease Post Operative Surgical Procedures | Recurrent disease Post Therapeutic radiology procedure

Data type

boolean

Alias
UMLS CUI [1]
C3258246
UMLS CUI [2,1]
C1273390
UMLS CUI [2,2]
C1272705
UMLS CUI [3,1]
C0277556
UMLS CUI [3,2]
C0687676
UMLS CUI [3,3]
C0543467
UMLS CUI [4,1]
C0277556
UMLS CUI [4,2]
C0687676
UMLS CUI [4,3]
C1522449
no prior chemotherapy except adjuvant chemotherapy and concurrent chemoradiation treatment. the last dose of adjuvant chemotherapy should be at least 6 months earlier from randomization, and the regimen should not contain docetaxel or pemetrexed.
Description

Prior Chemotherapy Absent | Exception Adjuvant Chemotherapy | Exception Concurrent Chemoradiotherapy | Docetaxel Absent | Pemetrexed Absent

Data type

boolean

Alias
UMLS CUI [1,1]
C1514457
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0085533
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C3178775
UMLS CUI [4,1]
C0246415
UMLS CUI [4,2]
C0332197
UMLS CUI [5,1]
C0210657
UMLS CUI [5,2]
C0332197
no prior immunotherapy, biologic therapy
Description

Prior Immunotherapy Absent | Biological treatment Absent

Data type

boolean

Alias
UMLS CUI [1,1]
C1514461
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C1531518
UMLS CUI [2,2]
C0332197
measurable lesion with response evaluation criteria in solid tumors (recist) version 1.1
Description

Measurable lesion

Data type

boolean

Alias
UMLS CUI [1]
C1513041
hemoglobin >=9.0g/dl, platelet >=100,000/ul, neutrophil >=1,500 /ul creatinine <=1.5 x upper normal limit or creatinine clearance >=60 ml/min bilirubin <=1.5 x upper normal limit, transaminases <=2 x upper normal limit alkaline phosphatase <=2 x upper normal limit
Description

Hemoglobin measurement | Platelet Count measurement | Neutrophil count | Creatinine measurement, serum | Creatinine clearance measurement | Serum total bilirubin measurement | Transaminase Assay | Alkaline phosphatase measurement

Data type

boolean

Alias
UMLS CUI [1]
C0518015
UMLS CUI [2]
C0032181
UMLS CUI [3]
C0200633
UMLS CUI [4]
C0201976
UMLS CUI [5]
C0373595
UMLS CUI [6]
C1278039
UMLS CUI [7]
C0919834
UMLS CUI [8]
C0201850
written informed consent
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
pregnancy, lactating woman
Description

Pregnancy | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
woman in child bearing age who refuses to do pregnancy test
Description

Childbearing Potential Pregnancy Test Refused

Data type

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0032976
UMLS CUI [1,3]
C1705116
moderate or greater than grade 1 motor or sensory neurotoxicity
Description

Neurotoxicity Motor Moderate | Neurotoxicity Sensory Moderate | Neurotoxicity Motor CTCAE Grades | Neurotoxicity Sensory CTCAE Grades

Data type

boolean

Alias
UMLS CUI [1,1]
C0235032
UMLS CUI [1,2]
C0026609
UMLS CUI [1,3]
C0205081
UMLS CUI [2,1]
C0235032
UMLS CUI [2,2]
C0027883
UMLS CUI [2,3]
C0205081
UMLS CUI [3,1]
C0235032
UMLS CUI [3,2]
C0026609
UMLS CUI [3,3]
C1516728
UMLS CUI [4,1]
C0235032
UMLS CUI [4,2]
C0027883
UMLS CUI [4,3]
C1516728
hypersensitivity to taxane
Description

Hypersensitivity Taxane

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0215136
comorbidity or poor medical conditions
Description

Comorbidity | Medical condition Poor

Data type

boolean

Alias
UMLS CUI [1]
C0009488
UMLS CUI [2,1]
C3843040
UMLS CUI [2,2]
C0542537
other malignancy (except cured basal cell carcinoma or uterine cervical carcinoma in situ)
Description

Cancer Other | Exception Basal cell carcinoma Cured | Exception Carcinoma in situ of uterine cervix Cured

Data type

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0007117
UMLS CUI [2,3]
C1880198
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0851140
UMLS CUI [3,3]
C1880198
concurrent treatment with other investigational drugs within 30 days before randomization
Description

Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C0013230
active treatment with other anticancer chemotherapy
Description

Antineoplastic Chemotherapy Regimen Other

Data type

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C0205394
egfr mutation (exon 19 deletion, l858r, l861q, g719a/c/s)
Description

EGFR gene mutation | EGFR exon 19 deletion | EGFR L858R | EGFR L861Q | EGFR G719A | EGFR G719C | EGFR G719S

Data type

boolean

Alias
UMLS CUI [1]
C3266992
UMLS CUI [2]
C3889117
UMLS CUI [3]
C3274204
UMLS CUI [4]
C3274186
UMLS CUI [5]
C3274209
UMLS CUI [6]
C3274211
UMLS CUI [7]
C3274216
Back to the top of the page

Similar models

Eligibility Carcinoma, Non Small Cell Lung NCT01282151

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
age >= 18 years old
boolean
C0001779 (UMLS CUI [1])
ECOG performance status
Item
ecog performance status 0-2
boolean
C1520224 (UMLS CUI [1])
Non-squamous non-small cell lung cancer
Item
non-squamous cell type non-small cell lung cancer (nsclc)
boolean
C4324656 (UMLS CUI [1])
TNM clinical staging | Curative treatment Unsuccessful | Recurrent disease Post Operative Surgical Procedures | Recurrent disease Post Therapeutic radiology procedure
Item
stage iv, stage iiib cannot be treated with curative intent or relapsed after surgery or radiation therapy
boolean
C3258246 (UMLS CUI [1])
C1273390 (UMLS CUI [2,1])
C1272705 (UMLS CUI [2,2])
C0277556 (UMLS CUI [3,1])
C0687676 (UMLS CUI [3,2])
C0543467 (UMLS CUI [3,3])
C0277556 (UMLS CUI [4,1])
C0687676 (UMLS CUI [4,2])
C1522449 (UMLS CUI [4,3])
Prior Chemotherapy Absent | Exception Adjuvant Chemotherapy | Exception Concurrent Chemoradiotherapy | Docetaxel Absent | Pemetrexed Absent
Item
no prior chemotherapy except adjuvant chemotherapy and concurrent chemoradiation treatment. the last dose of adjuvant chemotherapy should be at least 6 months earlier from randomization, and the regimen should not contain docetaxel or pemetrexed.
boolean
C1514457 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0085533 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C3178775 (UMLS CUI [3,2])
C0246415 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
C0210657 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
Prior Immunotherapy Absent | Biological treatment Absent
Item
no prior immunotherapy, biologic therapy
boolean
C1514461 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C1531518 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Measurable lesion
Item
measurable lesion with response evaluation criteria in solid tumors (recist) version 1.1
boolean
C1513041 (UMLS CUI [1])
Hemoglobin measurement | Platelet Count measurement | Neutrophil count | Creatinine measurement, serum | Creatinine clearance measurement | Serum total bilirubin measurement | Transaminase Assay | Alkaline phosphatase measurement
Item
hemoglobin >=9.0g/dl, platelet >=100,000/ul, neutrophil >=1,500 /ul creatinine <=1.5 x upper normal limit or creatinine clearance >=60 ml/min bilirubin <=1.5 x upper normal limit, transaminases <=2 x upper normal limit alkaline phosphatase <=2 x upper normal limit
boolean
C0518015 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
C0200633 (UMLS CUI [3])
C0201976 (UMLS CUI [4])
C0373595 (UMLS CUI [5])
C1278039 (UMLS CUI [6])
C0919834 (UMLS CUI [7])
C0201850 (UMLS CUI [8])
Informed Consent
Item
written informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Pregnancy | Breast Feeding
Item
pregnancy, lactating woman
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Childbearing Potential Pregnancy Test Refused
Item
woman in child bearing age who refuses to do pregnancy test
boolean
C3831118 (UMLS CUI [1,1])
C0032976 (UMLS CUI [1,2])
C1705116 (UMLS CUI [1,3])
Neurotoxicity Motor Moderate | Neurotoxicity Sensory Moderate | Neurotoxicity Motor CTCAE Grades | Neurotoxicity Sensory CTCAE Grades
Item
moderate or greater than grade 1 motor or sensory neurotoxicity
boolean
C0235032 (UMLS CUI [1,1])
C0026609 (UMLS CUI [1,2])
C0205081 (UMLS CUI [1,3])
C0235032 (UMLS CUI [2,1])
C0027883 (UMLS CUI [2,2])
C0205081 (UMLS CUI [2,3])
C0235032 (UMLS CUI [3,1])
C0026609 (UMLS CUI [3,2])
C1516728 (UMLS CUI [3,3])
C0235032 (UMLS CUI [4,1])
C0027883 (UMLS CUI [4,2])
C1516728 (UMLS CUI [4,3])
Hypersensitivity Taxane
Item
hypersensitivity to taxane
boolean
C0020517 (UMLS CUI [1,1])
C0215136 (UMLS CUI [1,2])
Comorbidity | Medical condition Poor
Item
comorbidity or poor medical conditions
boolean
C0009488 (UMLS CUI [1])
C3843040 (UMLS CUI [2,1])
C0542537 (UMLS CUI [2,2])
Cancer Other | Exception Basal cell carcinoma Cured | Exception Carcinoma in situ of uterine cervix Cured
Item
other malignancy (except cured basal cell carcinoma or uterine cervical carcinoma in situ)
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1880198 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0851140 (UMLS CUI [3,2])
C1880198 (UMLS CUI [3,3])
Investigational New Drugs
Item
concurrent treatment with other investigational drugs within 30 days before randomization
boolean
C0013230 (UMLS CUI [1])
Antineoplastic Chemotherapy Regimen Other
Item
active treatment with other anticancer chemotherapy
boolean
C0392920 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
EGFR gene mutation | EGFR exon 19 deletion | EGFR L858R | EGFR L861Q | EGFR G719A | EGFR G719C | EGFR G719S
Item
egfr mutation (exon 19 deletion, l858r, l861q, g719a/c/s)
boolean
C3266992 (UMLS CUI [1])
C3889117 (UMLS CUI [2])
C3274204 (UMLS CUI [3])
C3274186 (UMLS CUI [4])
C3274209 (UMLS CUI [5])
C3274211 (UMLS CUI [6])
C3274216 (UMLS CUI [7])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial